Biotech Hangout

Episode 113

Aug 27, 2024
The hosts dive into the implications of recent Medicare drug pricing changes and predict how political shifts might impact biotech mergers. They discuss the controversial closing of Genentech's cancer immunology group and Roche's strategic refocusing. Exciting innovations are highlighted, including advances in hypoparathyroidism treatments and new drugs for obesity-related heart failure. The World Health Organization's monkeypox announcement prompts a look at vaccine development, while upcoming lung cancer conferences stir anticipation for groundbreaking data.
Ask episode
Chapters
Transcript
Episode notes